| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Kelly, John
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (10/10 displayed)
- 2023Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cellscitations
- 2022Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant <i>Enterococcus faecium</i> (VREfm)citations
- 2021Radially Grown Graphene Nanoflakes for Tough and Strong Carbon Fiber Epoxy Compositescitations
- 2021Influence of Binder Float Length on the Out-of-Plane and Axial Impact Performance of 3D Woven Compositescitations
- 2020Improved crush energy absorption in 3D woven composites by pick density modificationcitations
- 2019Influence of Textile Architecture on the Mechanical Properties of 3D Woven Carbon Composites
- 2019Comparative studies of structure property relationship between glass/epoxy and carbon/epoxy 3D woven composites
- 2019Energy Absorption Mechanisms in Layer-to-Layer 3D Woven Composites
- 2019Improved Energy Absorption in 3D Woven Composites by Weave Parameter Manipulationcitations
- 2013Advances in the synthesis of ZnO materials for varistor devicescitations
Places of action
| Organizations | Location | People |
|---|
article
Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant <i>Enterococcus faecium</i> (VREfm)
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>There is in vitro and clinical evidence to suggest daptomycin has good activity against Enterococcus. In 2019, CLSI produced clinical breakpoints for Enterococcus spp.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>To describe the distribution of MICs of daptomycin for enterococcal bloodstream infection (EBSI) isolates in a large Scottish health board, the indications for local daptomycin susceptibility testing and daptomycin doses used in vancomycin-resistant Enterococcus faecium (VREfm) infection.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We investigated all EBSIs over a 21 month period and identified isolates tested against daptomycin. We recorded the distribution of MICs, as well as indications for daptomycin susceptibility testing and information on daptomycin dosing, where it was used.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>There were 293 blood culture isolates of Enterococcus spp., of which 37 had daptomycin susceptibility testing performed, from 31 individual patients. Of the 293 isolates, 103 were E. faecium, of which 63 were VREfm. Daptomycin testing was indicated by vancomycin resistance in 24/37 isolates. All E. faecium isolates tested were in the CLSI ‘susceptible dose-dependent (SDD)’ range of MICs. All other Enterococcus spp. tested were in the ‘susceptible’ range. Twelve patients received daptomycin, and dosing information was recovered for 10. Nine of these patients received 8–12 mg/kg/day dosing. There were no recorded adverse drug reactions. Ten of 12 patients were alive at the time of data collection.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Daptomycin MIC distribution for EBSI isolates suggests a high local rate of susceptibility, according to CLSI breakpoints, in a population with high rates of VREfm. CLSI-recommended doses of daptomycin were used, with encouraging survival outcomes.</jats:p></jats:sec>